Recce Pharmaceuticals Limited has officially received approval from the Canadian Patent Office for a new patent titled "Process for Preparation of Biologically Active Copolymer

Arcturus Therapeutics Holdings Inc. has recently announced that the U.S. Food and Drug Administration granted Orphan Drug Designation for ARCT-032, the company's product candidate for treating cystic fibrosis

Hemogenyx Pharmaceuticals plc has made a noteworthy expansion in the potential applications of its Chimeric Bait Receptor platform. Initially designed for treating viral diseases

Simcere Pharmaceutical Group Limited recently finalized an exclusive license and collaboration agreement with Connect Biopharma HongKong Limited concerning Rademikibart, an innovative IL-4Rα monoclonal antibody

Immutep Limited has expanded the INSIGHT-003 trial to include four sites across Germany, including the University Clinic of Ruhr Universität Bochum and the Lung Clinic Cologne-Merheim

Immutep Limited has expanded the INSIGHT-003 trial to include four sites across Germany, including the University Clinic of Ruhr Universität Bochum and the Lung Clinic Cologne-Merheim.

BeiGene, Ltd. and Ensem Therapeutics, Inc. have disclosed a strategic collaboration, wherein BeiGene will acquire an exclusive global license for an Investigational New Drug

MIRA Pharmaceuticals, Inc., has unveiled a strategic collaboration with MIRALOGX, LLC, an intellectual property holding company established by MIRA's founder. This partnership grants MIRA exclusive development

HOOKIPA Pharma Inc, a company focused on developing immunotherapeutics using its proprietary arenavirus platform, has received FDA clearance for its Investigational New Drug

Avistone Biotechnology Co. Ltd. has recently gained conditional approval from the National Medical Products Administration to market Vebreltinib, a precision oncology therapeutic,